highest dose of glp 1 🚨 FDA just approved Foundayo™ (orforglipron) — Lilly's once-daily oral GLP- for obesity. The headline: 12.4% average body weight reduction at the over 72 weeks in ATTAIN-1. That's −27 lbs TrimRX | What is the

Dulaglutide is not indicated in the treatment of subjects with type 1 diabetes or patients with diabetic ketoacidosis because these problems are the result of the islet cells being unable to produce insulin and one of the actions of dulaglutide is to stimulate functioning islet cells to produce more insulin

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) - Full Text View - ClinicalTrials.gov (n.d.)

Over 68 weeks, with a starting dose of 2 mg escalated every 4 weeks: 9 mg dose: 26.4% average body weight reduction (29.1 kg / 64.2 lbs) 12 mg dose: 28.7% average body weight reduction (32.3 kg / 71.2 lbs) Placebo: 2.1% average body weight reduction The milestone achievements tell an even more compelling story

doi: 10.4239/wjd.v12.i7.1042 2 GaberySSalinasCGPaulsenSJAhnfelt-RnneJAlanentaloTBaqueroAFet al